Sensitivity and specificity of tritiated thymidine incorporation and ELISPOT assays in identifying antigen specific T cell immune responses
Open Access
- 1 January 2007
- journal article
- Published by Springer Nature in BMC Immunology
- Vol. 8 (1) , 21
Abstract
Standardization of cell-based immunologic monitoring is becoming increasingly important as methods for measuring cellular immunity become more complex. We assessed the ability of two commonly used cell-based assays, tritiated thymidine incorporation (proliferation) and IFN-gamma ELISPOT, to predict T cell responses to HER-2/neu, tetanus toxoid (tt), and cytomegalovirus (CMV) antigens. These antigens were determined to be low (HER-2/neu), moderate (tt), and robustly (CMV) immunogenic proteins. Samples from 27 Stage II, III, and IV HER-2/neu positive breast cancer patients, vaccinated against the HER-2/neu protein and tt, were analyzed by tritiated thymidine incorporation and IFN-gamma ELISPOT for T cell response.Keywords
This publication has 19 references indexed in Scilit:
- Humoral and cellular immune responses to influenza vaccine in patients with advanced cirrhosisVaccine, 2006
- Laboratory Analysis of T-Cell ImmunityFrontiers in Bioscience-Landmark, 2006
- Immune Activation at Effector and Gene Expression Levels After Measles Vaccination in Healthy Individuals: A Pilot StudyHuman Immunology, 2005
- Human tumor cell lysates as a protein source for the detection of cancer antigen-specific humoral immunityJournal of Immunological Methods, 2005
- Effect of Dose on Immune Response in Patients Vaccinated With an HER-2/neu Intracellular Domain Protein—Based VaccineJournal of Clinical Oncology, 2004
- Autoantibodies in autoimmune thyroid disease promote immune complex formation with self antigens and increase B cell and CD4+ T cell proliferation in response to self antigensEuropean Journal of Immunology, 2003
- Monitoring of immune responses to CA125 with an IFN-γ ELISPOT assayJournal of Immunological Methods, 2003
- Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian CancerNew England Journal of Medicine, 2003
- Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor LymphocytesScience, 2002
- Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patientsJournal of Clinical Investigation, 2001